• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环缩肽apratoxin A及其类似物的全合成及其生物活性评估。

Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities.

作者信息

Ma Dawei, Zou Bin, Cai Guorong, Hu Xiaoyi, Liu Jun O

机构信息

State Key Laboratory of Bioorganic and Natural Products Chemistry Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences 354 Fenglin Lu, Shanghai 200032, China.

出版信息

Chemistry. 2006 Oct 10;12(29):7615-26. doi: 10.1002/chem.200600599.

DOI:10.1002/chem.200600599
PMID:16832801
Abstract

A novel total synthesis of apratoxin A is described, with key steps including the assembly of its ketide segment through a D-proline-catalyzed direct aldol reaction and Oppolzer's anti aldol reaction and the preparation of its thiazoline unit in a biomimetic synthesis. An oxazoline analogue of apratoxin A has also been elaborated by a similar approach. This compound has a potency against HeLa cell proliferation only slightly lower than that of apratoxin A, whilst a C(40)-demethylated oxazoline analogue of apratoxin A displays a much lower cytotoxicity and the C(37)-epimer and C(37) demethylation product of this new analogue are inactive. These results suggest that the two methyl groups at C(37) and C(40) and the stereochemistry at C(37) are essential for the potent cellular activity of the oxazoline analogue of apratoxin A. Further biological analysis revealed that both synthetic apratoxin A and its oxazoline analogue inhibited cell proliferation by causing cell cycle arrest in the G1 phase.

摘要

本文描述了一种新的海兔毒素A的全合成方法,关键步骤包括通过D-脯氨酸催化的直接羟醛反应和奥波泽尔反式羟醛反应构建其聚酮片段,以及通过仿生合成制备其噻唑啉单元。还通过类似方法制备了海兔毒素A的恶唑啉类似物。该化合物对HeLa细胞增殖的抑制活性仅略低于海兔毒素A,而海兔毒素A的C(40)-去甲基化恶唑啉类似物的细胞毒性则低得多,并且该新类似物的C(37)-差向异构体和C(37)去甲基化产物无活性。这些结果表明,C(37)和C(40)位的两个甲基以及C(37)位的立体化学结构对海兔毒素A恶唑啉类似物的强效细胞活性至关重要。进一步的生物学分析表明,合成的海兔毒素A及其恶唑啉类似物均通过使细胞周期停滞在G1期来抑制细胞增殖。

相似文献

1
Total synthesis of the cyclodepsipeptide apratoxin A and its analogues and assessment of their biological activities.环缩肽apratoxin A及其类似物的全合成及其生物活性评估。
Chemistry. 2006 Oct 10;12(29):7615-26. doi: 10.1002/chem.200600599.
2
Synthesis of an oxazoline analogue of apratoxin A.阿普拉毒素A的恶唑啉类似物的合成
Org Lett. 2003 Sep 18;5(19):3503-6. doi: 10.1021/ol035332y.
3
Total synthesis of (-)-apratoxin A, 34-epimer, and its oxazoline analogue.(-)-阿普拉毒素A、34-差向异构体及其恶唑啉类似物的全合成。
Chem Asian J. 2009 Jan 5;4(1):111-25. doi: 10.1002/asia.200800365.
4
Synthesis of the biologically active natural product cyclodepsipeptides apratoxin A and its analogues.生物活性天然产物环缩肽apratoxin A及其类似物的合成。
Chem Pharm Bull (Tokyo). 2014;62(8):735-43. doi: 10.1248/cpb.c14-00268.
5
Solid-phase total synthesis of (-)-apratoxin A and its analogues and their biological evaluation.固相全合成 (-)-阿朴托毒素 A 及其类似物及其生物评价。
Chem Asian J. 2011 Jan 3;6(1):180-8. doi: 10.1002/asia.201000549.
6
A functional genomics approach to the mode of action of apratoxin A.一种针对海兔毒素A作用模式的功能基因组学方法。
Nat Chem Biol. 2006 Mar;2(3):158-67. doi: 10.1038/nchembio769. Epub 2006 Feb 12.
7
Supported synthesis of oxoapratoxin A.
J Org Chem. 2009 Jun 5;74(11):4298-304. doi: 10.1021/jo900583j.
8
Potent oxazoline analog of apratoxin C: Synthesis, biological evaluation, and conformational analysis.Apratoxin C的强效恶唑啉类似物:合成、生物学评价及构象分析。
Biopolymers. 2016 Nov 4;106(4):404-14. doi: 10.1002/bip.22781.
9
Synthesis and structure-activity correlation of natural-product inspired cyclodepsipeptides stabilizing F-actin.具有天然产物启发的环二肽稳定 F-肌动蛋白的合成及构效关系。
J Am Chem Soc. 2010 Mar 10;132(9):3063-77. doi: 10.1021/ja9095126.
10
Total synthesis of apratoxin A.阿普拉毒素A的全合成。
J Am Chem Soc. 2003 Jul 23;125(29):8734-5. doi: 10.1021/ja036050w.

引用本文的文献

1
Progress in the discovery and development of anticancer agents from marine cyanobacteria.从海洋蓝细菌中发现和开发抗癌药物的进展。
Nat Prod Rep. 2025 Feb 19;42(2):208-256. doi: 10.1039/d4np00019f.
2
Marine-Derived Anticancer Agents Targeting Apoptotic Pathways: Exploring the Depths for Novel Cancer Therapies.海洋来源的靶向细胞凋亡通路的抗癌药物:探索新型癌症治疗方法的深度。
Mar Drugs. 2024 Feb 28;22(3):114. doi: 10.3390/md22030114.
3
Marine Cyanobacteria and Microalgae Metabolites-A Rich Source of Potential Anticancer Drugs.海洋蓝细菌和微藻代谢产物——潜在抗癌药物的丰富来源。
Mar Drugs. 2020 Sep 19;18(9):476. doi: 10.3390/md18090476.
4
Marine Natural Products: A Source of Novel Anticancer Drugs.海洋天然产物:新型抗癌药物的来源。
Mar Drugs. 2019 Aug 23;17(9):491. doi: 10.3390/md17090491.
5
Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.海洋来源抗癌肽的治疗特性和生物益处。
Int J Mol Sci. 2018 Mar 20;19(3):919. doi: 10.3390/ijms19030919.
6
Apratoxin S10, a Dual Inhibitor of Angiogenesis and Cancer Cell Growth To Treat Highly Vascularized Tumors.阿普拉毒素S10,一种血管生成和癌细胞生长的双重抑制剂,用于治疗高度血管化肿瘤。
ACS Med Chem Lett. 2017 Sep 18;8(10):1007-1012. doi: 10.1021/acsmedchemlett.7b00192. eCollection 2017 Oct 12.
7
Improved total synthesis and biological evaluation of potent apratoxin S4 based anticancer agents with differential stability and further enhanced activity.改良的强效 apratoxin S4 型抗癌剂的全合成与生物评估,该抗癌剂具有不同的稳定性和进一步增强的活性。
J Med Chem. 2014 Apr 10;57(7):3011-29. doi: 10.1021/jm4019965. Epub 2014 Mar 24.
8
Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.基于肽的药物的现状:阳离子抗肿瘤和抗病毒肽的关键作用。
Front Microbiol. 2013 Oct 31;4:321. doi: 10.3389/fmicb.2013.00321. eCollection 2013.
9
Apratoxin H and apratoxin A sulfoxide from the Red Sea cyanobacterium Moorea producens.来源于红海蓝藻 Moorea producens 的阿普拉毒素 H 和阿普拉毒素 A 亚砜。
J Nat Prod. 2013 Sep 27;76(9):1781-8. doi: 10.1021/np4004992. Epub 2013 Sep 9.
10
A survey of marine natural compounds and their derivatives with anti-cancer activity reported in 2011.2011 年报道的具有抗癌活性的海洋天然化合物及其衍生物的调查。
Molecules. 2013 Mar 25;18(4):3641-73. doi: 10.3390/molecules18043641.